Table 3. Incidence and risk difference (RD) of self-reported fever episodes among household members that attended the mass drug administration (MDA) of artesunate/amodiaquine malaria chemoprevention (ASAQ-CP) in rounds 1 and 2 during the Ebola outbreak, Monrovia, Liberia, 2014.

Responses for all household members		Incidence of self-reported fever episodes (%) in the month prior to round 1	Incidence of self-reported fever episodes (%) in the month prior to round 2	RD (%) of self-reported fever episodes	(95% CI for RD)	p-value
All household members (N = 1229ᶲ)		4.2	1.5	2.7	(1.4; 4.0)	<0.001*
Incidence of self-reported fever by ASAQ-CP adherence
	Household members who completed ASAQ-CP in round 1 (N = 592‡)	6.4	1.5	4.9	(2.7; 7.1)	<0.001*
	Household members who did not start or complete ASAQ-CP in round 1 (N = 511‡)	2.2	1.6	0.6	(-1.1; 2.2)	0.690
Incidence of self-reported fever by age group
	Household members >5 years old (N = 1044)	3.8	1.6	2.2	(0.8; 3.6)	0.002*
	Household members < = 5 years old (N = 185)	6.5	1.1	5.4	(1.6; 9.2)	0.006*

ᶲ 6 household members for whom incidence of self-reported fever is unknown were excluded

^‡ Further 126 household members for whom compliance with ASAQ-CP initiation or adherence was unknown were excluded from analysis

* Significant difference in incidence of self-reported fever between round 1 and 2 of the MDA